Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracill-leucovorin for the adjuvant treatment of colon cancer in Japan

PharmacoEconomics

Volumn 27, Issue 7, 2009, Pages 597-608

  Shiroiwa, Takeru ^a   Fukuda, Takashi ^a   Shimozuma, Kojiro ^b   Ohashi, Yasuo ^a   Tsutani, Kiichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID;

ADJUVANT THERAPY; ADULT; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER STAGING; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; FEMALE; HAND FOOT SYNDROME; HEALTH INSURANCE; HUMAN; INFECTION; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL ANALYSIS; VOMITING;

ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; JAPAN; LEUCOVORIN; MALE; MARKOV CHAINS; MIDDLE AGED;

EID: 68949099368     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11310110-000000000-00000     Document Type: Article

References (31)

1. Ministry of Health, Labour and Welfare. Population survey report [in Japanese]. Tokyo: Ministry of Health, Labour and Welfare, 2006
2. Center for Cancer Control and Information Services, National Cancer Center, Japan. Regional cancer records and estimated national figures [in Japanese]. Tokyo: Center for Cancer Control and Information Services, National Cancer Center, 2007
3. Cilley J, Mulcahy MF. Adjuvant therapy for colon cancer. Curr Oncol Rep 2006; 8 (3): 161-166
4. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80 (1): 30-36 (Pubitemid 18076566)
5. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose LV given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15(1): 246-250
6. Wolmark N, Rockette H, Fisher B, et al. The benefit of LV-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11 (10): 1879-1887
7. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-944
8. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350 (23): 2343-2351
9. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25 (16): 2198-2204
10. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352 (26): 2696-2704
11. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281
12. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297
13. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluor-ouracil/LV. Ann Oncol 2002; 13: 566-575
14. Twelves C, Gollins S, Grieve R, et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17 (2): 239-245
15. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine versus intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94 (8): 1122-1129
16. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23 (34): 8671-8678
17. Hyodo I, Shirao K, Doi T, et al. A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2006; 36 (7): 410-417
18. Japanese Society for Cancer of the Colon and Rectum, editor. Colon cancer treatment guidelines [in Japanese]. Tokyo: Kanehara Shuppan, 2005
19. Monz BU, König HH, Leidl R, et al. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany. Pharmacoeconomics 2003; 21 (10): 709-719
20. Aballéa S, Chancellor JV, Raikou M, et al. Cost-effective-ness analysis of oxaliplatin compared with 5-fluorouracil/ leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007; 109 (6): 1082-1089
21. Aballéa S, Boler A, Craig A, et al. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer 2007; 43 (11): 1687-1693
22. Twelves C, Scheithauer W, McKendrick J, et al. 5-year overall survival update from the X-ACT trial of capecitabine versus 5-FU/LV as adjuvant treatment for stage III colon cancer [abstract]. Presented at ECCO Oncology Conference 14; 2007 Sep 23-27; Barcelona
23. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-1258
24. Reimbursement schedule of social insurance and insurance for the elderly [in Japanese]. Tokyo: Social Insurance Research Laboratory, 2006
25. National health insurance drug price standard [in Japanese]. Tokyo: Jiho, 2005
26. Kris MG, Hesketh PJ, Somerfield MR. An American Society of Clinical Oncology guideline for antiemetics in oncology: update, 2006. J Clin Oncol 2006; 24: 2932-2947
27. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237
28. Ramsey S, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 88: 1294-1303
29. National Institute for Health and Clinical Excellence. Capecitabine and oxaliplatin, the adjuvant treatment of stage III (Dukes' C) colon cancer, 2006 [online]. Available from URL: http://www.nice.org.uk/guidance/index.jsp? action=download&o=33265. [Accessed 2007 Nov 1]
30. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004 [online]. Available from URL: http://www.nice.org. uk/page.aspx?o=201974 [Accessed 2007 Nov 1]
31. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus LV compared with intravenous fluorouracil and LV in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24 (13): 2059-2064